24 completed, 4 recruiting, 2 terminated, 1 active not recruiting. 21 Phase 1, 16 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 21 | Completed 17, Active not recruiting 1, Recruiting 1, Suspended 1, Terminated 1 |
| Phase 2 | 16 | Completed 12, Recruiting 3, Terminated 1 |
Follow Previously Treated Myelodysplastic Syndrome: new trials by email Literature Review of Previously Treated Myelodysplastic Syndrome trials Research Report on Previously Treated Myelodysplastic Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome Ibrutinib, Lenalidomide - Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome | Phase 1 | Completed | University of California, Davis | 4 | 2017-12-01 | 2026-03-10 |
| Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia Decitabine, Ipilimumab - Previously Treated Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 54 | 2017-09-05 | 2026-09-09 |
| WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome Cytarabine, Laboratory Biomarker Analysis, Pharmacological Study - Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome With Isolated Del(5q) | Phase 2 | Completed | Mayo Clinic | 3 | 2017-05-05 | 2019-09-06 |
| Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent Azacitidine, Decitabine, Laboratory Biomarker Analysis - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia | Phase 2 | Terminated | University of Southern California | 7 | 2017-04-20 | 2026-06-08 |
| A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - B-Cell Non-Hodgkin Lymphoma, Histiocytic and Dendritic Cell Neoplasm | Phase 1 | Recruiting | Mayo Clinic | 99 | 2017-04-04 | 2026-06-10 |
| Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS Cladribine, Cytarabine, Decitabine - Mixed Phenotype Acute Leukemia, Previously Treated Myelodysplastic Syndrome | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 28 | 2016-11-17 | 2020-03-17 |
| Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms Cladribine, Cyclosporine, Cytarabine - Blasts 10 Percent or More of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia-2 | Phase 2 | Completed | University of Washington | 30 | 2016-09-22 | 2021-11-08 |
| Personalized NK Cell Therapy in CBT Allogeneic Natural Killer Cell Line NK-92, Anti-Thymocyte Globulin, Busulfan - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 100 | 2016-05-19 | 2026-07-30 |
| Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome Azacitidine, Ibrutinib - Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome | Phase 1 | Completed | Brian Jonas | 21 | 2016-05-17 | 2022-10-06 |
| Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Leukemia Bone Marrow Transplantation, Cyclophosphamide, Fludarabine Phosphate - Adult Acute Lymphoblastic Leukemia in Complete Remission, Acute Myeloid Leukemia in Remission | Phase 1 | Completed | City of Hope Medical Center | 31 | 2015-06-25 | 2025-06-22 |
| Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant Fludarabine Phosphate, Melphalan, Intensity-Modulated Radiation Therapy - Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia | Phase 1 | Suspended | University of Chicago | 30 | 2014-12-05 | 2026-03-30 |
| Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia Cladribine, Cytarabine, Gilteritinib - Acute Biphenotypic Leukemia, Acute Myeloid Leukemia | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 508 | 2014-05-19 | 2026-05-20 |
| Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies Azacitidine, Decitabine, Laboratory Biomarker Analysis - Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome | Phase 1 | Completed | Mayo Clinic | 63 | 2014-05-01 | 2019-10-30 |
| Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin - Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission | Phase 1 | Completed | M.D. Anderson Cancer Center | 70 | 2014-03-06 | 2022-01-06 |
| Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Cladribine, Cytarabine, Filgrastim - Acute Biphenotypic Leukemia, de Novo Myelodysplastic Syndrome | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 199 | 2014-01-23 | 2020-01-10 |
| Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Erlotinib Hydrochloride, Laboratory Biomarker Analysis - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 | Phase 2 | Completed | M.D. Anderson Cancer Center | 29 | 2013-05-16 | 2020-01-07 |
| Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Cytarabine, Decitabine, Etoposide - Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 52 | 2012-12-20 | 2019-02-07 |
| Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Ipilimumab, Laboratory Biomarker Analysis - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 42 | 2012-12-14 | 2018-03-21 |
| Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome Anti-Thymocyte Globulin, Cyclosporine, Filgrastim - Aplastic Anemia, de Novo Myelodysplastic Syndrome | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 140 | 2012-06-25 | 2026-06-22 |
| Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine - Chronic Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndrome | Phase 1 | Completed | Fred Hutchinson Cancer Center | 16 | 2012-01-01 | 2019-12-10 |
Showing 20 of 32. Sign in to see all of them.
Leukemia, Myeloid, Acute (26) · Leukemia, Myelomonocytic, Chronic (13) · Myelodysplastic Syndromes (12) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (11) · Leukemia, Myelomonocytic, Acute (6) · Leukemia, Promyelocytic, Acute (6) · Anemia, Refractory, with Excess of Blasts (5) · Blast Crisis (4) · Hodgkin Disease (4) · Leukemia, Biphenotypic, Acute (4) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (4) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Lymphoma, Non-Hodgkin (3) · Multiple Myeloma (3) · Myelodysplastic-Myeloproliferative Diseases (3)
Hematologic Diseases (32) · Hemic and Lymphatic Diseases (32) · Neoplasms (29) · Neoplasms by Histologic Type (29) · Leukemia (28) · Leukemia, Myeloid (28) · Bone Marrow Diseases (25) · Chronic Disease (17) · Disease Attributes (17) · Pathologic Processes (17) · Pathological Conditions, Signs and Symptoms (17) · Immune System Diseases (15) · Immunoproliferative Disorders (15) · Lymphatic Diseases (15) · Lymphoproliferative Disorders (15)
fludarabine phosphate (13) · Mycophenolic Acid (11) · Whole-Body Irradiation (9) · Cytarabine (8) · Cyclosporine (7) · Peripheral Blood Stem Cell Transplantation (7) · Cyclophosphamide (6) · Cyclosporins (6) · Decitabine (6) · Injections (6) · Azacitidine (5) · Filgrastim (5) · Granulocyte Colony-Stimulating Factor (5) · Tacrolimus (5) · Cladribine (4)
Fred Hutchinson Cancer Center (10) · National Cancer Institute (NCI) (7) · M.D. Anderson Cancer Center (5) · Mayo Clinic (3) · Brian Jonas (1) · City of Hope Medical Center (1) · Masonic Cancer Center, University of Minnesota (1) · University of California, Davis (1) · University of Chicago (1) · University of Southern California (1) · University of Washington (1)
United States (32) · Germany (2) · Brazil (1) · Canada (1) · Denmark (1) · Italy (1) · New Zealand (1)
Brenda Sandmaier (5) · Brian Jonas (2) · Jorge Cortes (2) · Roland Walter (2) · Tapan M Kadia (2) · Alice Mims (1) · Anna Halpern (1) · Aref Al-Kali (1) · B. Smith (1) · Casey O'Connell, MD (1) · Christen Ebens, MD (1) · Hans-Peter Kiem (1) · Hongtao Liu (1) · Jacqueline S Garcia (1) · Johnnie Orozco (1)
PMID 32499241, PMID 20952518, PMID 25085357, PMID 26577691, PMID 29567781, PMID 29702001, PMID 31582553, PMID 32077361, PMID 32777116, PMID 34329576, PMID 35175355, PMID 36706355, PMID 36898933, PMID 37939122, PMID 40193193, PMID 40500616
P30CA015704 (10), P01CA044991 (3), P30CA016672 (3), P01CA018029 (2), P30CA014599 (2), P30CA015083 (2), P30CA016058 (2), U01CA076576 (2), P01CA078902 (1), P30CA006973 (1), P30CA014089 (1), P30CA093373 (1), P50CA186781 (1), R01CA211044 (1), R01CA262613 (1)